Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study

Siyi Zou†, Xinjing Wang†, Haoda Chen†, Jiewei Lin, Chenlei Wen, Qian Zhan, Hao Chen, Xiongxiong Lu, Xiaxing Deng and Baiyong Shen

Abstract

**Background:** Prognosis for patients recurred rapidly after resection of pancreatic ductal adenocarcinoma (PDAC) was extremely poor. We proposed the concept of postoperative hyper-progression disease (PO-HPD) to define recurrence within 2 months after surgery, explored the role of surgery for postoperative HPD patients and determined the predictive preoperative risk factors and genomic features of PO-HPD.

**Methods:** 976 patients undergoing curative resection of PDAC were enrolled. Survival data of 1733 stage IV patients from the US Surveillance, Epidemiology and End Results database was also collected. Patients relapsed were grouped into 3 groups regarding of the recurrence time (within 2 months were PO-HPD, within 2 to 12 months were early recurrence (ER) and within > 12 months were late recurrence (LR)). Risk factors for PO-HPD were explored with logistic regression models. Genomic features of 113 patients were investigated using next-generation sequencing-based gene panel testing.

**Results:** 718 of 976 cases relapsed, 101 were PO-HPD, 418 were ER and 199 were LR. Total survival of PO-HPD was 12.5 months, shorter than that of ER (16.7 months) and LR (35.1 months), and verged on that of stage IV patients (10.6 months). Preoperative risk factors for PO-HPD included red blood cell count < 3.94*10^12/L, CA19–9 ≥ 288.6 U/mL, CA125 ≥ 22.3 U/mL and tumor size ≥ 3.45 cm. Mutations of CEBPA, ATR and JAK1 were only identified in PO-HPD and they owned lower level of CN gain compared to others.

**Conclusions:** Prognosis of PO-HPD was extremely poor and the role of surgery for PO-HPD should be prudently assessed.

**Keywords:** Pancreatic ductal adenocarcinoma, Postoperative hyper-progression disease, Curative resection

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
because of the propensity of early recurrence and lack of effective systemic therapies, resulting in a 5-year survival of only 12–27% [3].

The definition of hyperprogression disease (HPD) was that the tumor burden has increased by > 50% or the tumor has grown more than twice the rate than that at the baseline, after a specific treatment within 2 months [4]. Patients with HPD are generally related to worse prognosis. The term, HPD, was mostly utilized in the field of immunotherapy; however, growth-stimulating effects from surgery were also observed in previous studies [5], and there were certain number of patients who developed rapid recurrence after curable-intent surgery for PDAC and died from uncontrolled disease progression. Differing from the unchallenged effect of surgery on patients with early recurrence, the role of surgery for HPD patients should be prudently assessed, given the poor survival benefit that the HPD patients gained from surgery and the high risk of postoperative complications.

The traditional definition of HPD based on tumor growth rate was not applicable for postoperative patients since there was no residual tumor after curable-intent surgery in theory. In this study, we aimed to propose the concept of postoperative hyperprogression disease (PO-HPD) for PDAC to clarify recurrence within 2 months after curable-intent resection, explore the role of surgery for postoperative HPD patients, and determine the predictive factors based on preoperative clinicophysiological findings. Further, we investigated genomic features of PO-HPD patients to identify genomic determinants and potential therapeutic alterations for PO-HPD.

Methods

Patients and data source

We retrospectively included patients undergoing curative-intent pancreatectomy between June 2009 and 2019 in Ruijin Hospital (Shanghai, China) for clinicopathologically diagnosed PDAC. Exclusion criteria were stage-IV tumors, R2 resection, history of neoadjuvant therapy, incomplete clinical data, and perioperative mortality. Based on these criteria, 976 patients were enrolled in this study.

We collected survival data of stage-IV (American Joint Committee on Cancer [AJCC] Stage Group) PDAC (International Classification of Diseases for Oncology, third edition, ICD-O-3 histology/behavior codes: 8140/3 and 8500/3) from the US Surveillance, Epidemiology, and End Results (SEER) database and enrolled 1733 patients with pathologically diagnosed PDAC at stage IV between 2010 and 2015.

Data collection

The perioperative clinical records, preoperative radiological diagnosis, and surgery reports of operating patients were reviewed. The surgical procedure was based on the principles of surgical technique of the National Comprehensive Cancer Network (NCCN) guidelines and conducted by experienced surgeons [6].

Collected data comprised pre- and postoperative demographics, clinicopathological characteristics, treatment options, and follow-up information. Body mass index was calculated as weight in kilograms (kg) divided by the height in meters squared (m²). The data on inflammation-based prognostic scores, systemic inflammatory response index (SIRI), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio, and lymphocyte-monocyte ratio, reported in other studies were also included in the present analysis. SIRI was calculated as NLR multiplied by monocyte count (10⁹/L). All the laboratory data were collected within 1 week before surgery. The resectability status was measured based on the contrast-enhanced abdominoperineal computed tomography within 2 weeks before surgery, referring to the NCCN guidelines. Vascular resection was defined as complete resection of invasive major vascular components including portal vein, superior mesenteric vein, superior mesenteric artery, common hepatic artery, and celiac trunk artery. The resection margin of R0 was defined as completely excised tumors with microscopic margin involvement of > 1 mm. Margin distance was the distance of carcinoma cells to the closest resection margin. Tumor stage was defined following the 8th edition of AJCC TNM staging manual [6]. Postoperative complications were stratified according to the Clavien-Dindo classification [7]. Postoperative pancreatic fistula (POPF) was diagnosed and classified based on the International Study Group of Pancreatic Fistula (ISGPF) criteria [8].

Recurrence

The recurrence was diagnosed on the basis of emerging suspicious lesions and elevated carbohydrate antigen (CA) 19–9, and was confirmed by fluorodeoxyglucose positron emission tomography or biopsy, if necessary. Recurrence patterns were classified into four groups: “local” was defined as recurrence in the remnant pancreas or in the surgical bed, such as soft tissue along the celiac or superior mesenteric artery, aorta, or around the pancreaticojejunoanostomy site; “systemic” was defined as recurrence occurring in distant sites, “multiple” included patients with both local and systemic recurrence, and “unknown” was defined as patients with sharply elevated CA19–9 but without further radiological imaging.
Follow-up
For the follow-up management, patients were required to visit during the postoperative 4–8 weeks for assessment of pre-adjuvant therapy. Physical examination, laboratory tests, and radiological imaging were conducted every 2–3 months after surgery in the first 2 years, followed by visits every 6 months as long as recurrence was detected. The start dates of the overall survival (OS) and disease-free survival (DFS) were the date of surgical resection. For the OS, the end point was the date of death or the last follow-up. For the DFS, the end point was the date of recurrence in any form, date of death from cancer-related cause or the last follow-up.

Patient cohort
Referring to the timing of recurrence, relapse patients were grouped into three cohorts: patients suffering recurrence within 2 months of surgery were defined as PO-HPD, patients suffering recurrence between 2 and 12 months after surgery were defined as early recurrence (ER) [9], and patients suffering recurrence later than 12 months post-surgery were defined as late recurrence (LR).

Single-nucleotide variants (SNV) variant calling
Formalin-fixed paraffin-embedded tumor tissue specimens and matched whole blood DNA were collected for next-generation sequencing (NGS) analysis. Mutations were identified using the NimbleGen SeqCap EZ Library (Roche, Wisconsin, USA), which included major tumor-related genes. The captured samples were then subjected to Novaseq 6000 processing for paired-end sequencing. VarDict (version 1.5.1) [10] was used to identify SNV mutations, while compound heterozygous mutations were merged by FreeBayes (version 1.2.0) [11], and annotated through ANNOVAR (version 20,210,710) [12]. The somatic mutations were identified after filtering germline mutations, and the final somatic mutations used for further analysis were separated based on the following standards: (i) frequency ≥5%; (ii) not located in intergenic regions or intronic regions and not synonymous SNVs; (iii) support reads ≥5; (iv) allele frequency ≤0.2% in the database Exome Aggregation Consortium (ExAC) and Genome Aggregation Database (gnomAD) [13].

Tumor mutational burden (TMB) calculation
After filtering germline mutations, we selected SNV mutations according to the following rules: (i) splicing type or exonic region; (ii) depth ≥100× and allele frequency ≥5%; (iii) allele frequency ≤0.2% in the ExAC database and gnomAD; and (iv) mutations without strand bias. The TMB was calculated with the formula:

\[ TMB = \frac{\text{absolute mutation counts} \times 1,000,000}{\text{panel exonic base number}} \]

Copy number variant (CNV) CONTRA calling
CNV mutations were paired via software ctCNV with copy number (CN) threshold 4 for CN gain and 1 for CN loss after filtering CNV mutation spot that is larger than 5 about bin number.

Copy number instability (CNI) score calculation
After correction of G-C content and length of target region using proprietary algorithms for each region, the read counts were transformed into log2 ratios and converted into Z-score based on gaussian transformations versus a normal control group (n = 30). The target regions that satisfied the Z-score greater than the 95th percentile plus twice the absolute standard deviation of the normal control group were retained, and these Z-scores were summed as the CNI score.

Mutant allele tumor heterogeneity (MATH) calculation
With the variant allele frequencies (VAF) calculated by the ratio of alternate allele observations to the read depth at each position, the MATH score was modified including all somatic variants with VAF from 0.02 to 1 according to the formula: 100 × median absolute deviation (MAD)/median of the VAF.

Statistical analysis
Continuous data are presented as mean (standard deviation [SD]) or median (inter-quartile range [IQR]) according to data distribution, while categorical data are presented as percentage (%). Characteristics’ comparison according to the subgroups were conducted using the chi-square test or Fisher’s exact test and the Mann–Whitney or the Kruskal–Wallis test. Receiver operating characteristic (ROC) analysis was performed to determine the cut-off value for significant continuous variables. Survival analysis was conducted using the Kaplan–Meier method and log-rank test. Univariable and multivariable logistic regression analyses were performed to identify the risk factors for HPD. All statistical analyses were conducted using SPSS software (IBM SPSS Statistics 22.0) and R (https://www.r-proje ct.org/, version 3.6.2), and a P value <0.05 was considered statistically significant.

Results
Baseline clinicopathological features and follow-up
Between June 2009 and 2019, 1222 patients were pathologically diagnosed with stages I-III PDAC and underwent curable-intent surgery, of which 18 (1.5%) patients who died of postoperative complications, 67 (5.5%) with
R2 resection, and 267 (21.8%) with incomplete follow-up data were excluded. A total of 976 patients were enrolled in this study for final analysis. Among the relapse patients, 101 (14.1%) were grouped into PO-HPD, 418 (58.2%) into ER, and 199 (27.7%) into LR.

Baseline demographic, clinicopathological, and treatment characteristics and follow-up data of the entire included population were dichotomized by the presence of recurrence as shown in Table 1. Among the whole patients enrolled, 377(38.6%) were female and the mean age was 62.5 (±8.8) years.

For the postoperative outcomes, 433 (44.4%) patients occurred biochemical leak and 134 (13.7%) patients occurred Grade B/C POPF. A total of forty-two (4.3%) patients suffered from severe complications (Clavien-Dindo classification III and higher), of which 26 (2.7%) patients underwent second operations. For patients required reoperations, 18 owing to abdominal bleeding, 6 owing to severe POPF or infection due to severe leak with inadequate drainage and 2 owing to pseudoaneurysm.

Median follow-up for the entire group was 21.7 (95% confidence interval [CI] 20.0–23.4) months. Of the 976 patients, 718 (73.6%) showed relapse during follow-up with a median DFS of 7.6 (95% CI 7.0–8.1) months and median OS of 15.7 (95% CI 10.0–23.4) months. Systemic recurrence (n = 390, 54.3%) was the most common, and liver metastasis ranked the first in prevalence (n = 277, 71.0%), followed by peritoneal dissemination (n = 84, 21.5%), lung metastasis (n = 26, 6.7%), and osseous metastasis (n = 3, 0.7%). Patients with multiple metastasis had the worst prognosis with median OS of 15.4 (95% CI 12.4–18.4) months followed by systemic recurrence with median OS of 16.8 (95% CI 15.3–18.3) months, unknown recurrence with median OS of 18.3 (95% CI 14.2–22.4) months, and local recurrence with median OS of 25.9 (95% CI 23.2–28.7) months.

Comparison results between recurrence and no recurrence groups showed that the former had higher preoperative level of inflammation-related values (neutrophil count, NLR, and SIRI) and tumor markers (CA19–9, CA125, and CEA), more borderline resectable tumors, and larger tumors. Rates of vascular resection and non-R0 resection were also higher in the recurrence group. Pathological findings confirmed that the tumors in the recurrence group showed more aggressive behavior.

Comparison among groups regarding recurrence time

As shown in Table 2, preoperative comparison of characteristics showed that the mean age of ER patients was higher than that in the other two groups, LR patients had higher level of monocyte, and PO-HPD patients had higher level of CA125 and CA19–9. The tumors of patients with shorter DFS exhibited lower R0 resection rates, more aggressive pathobiological behaviors, including larger size, poorer differentiation, more lymphovascular invasion, and higher AJCC stage. Adjuvant therapy did not differ between the cohorts. Regarding the patterns of recurrence, patients with PO-HPD mainly showed the occurrence of multiple (12.9%) and systemic metastases (66.3%).

Survival analysis among cohorts

Figure 1 depicts the Kaplan–Meier curves of total survival in PO-HPD, ER, and LR groups. Median OS significantly decreased in each cohort with 9.8 (95% CI 7.8–11.7) months for PO-HPD, 14.7 (95% CI 13.9–15.8) months for ER, and 30.8 (95% CI 29.1–32.5) months for LR. Considering the extremely poor outcome of PO-HPD group, we further compared the PO-HPD and stage-IV patients. Survival data of PO-HPD and stage-IV patients from SEER are listed in Table 3. The total survival was counted from the date of diagnosis of pancreatic cancer to the date of death or last follow-up. Compared with stage-IV patients (10.7 months), PO-HPD patients (12.5 months) only had less than two additional months of median total survival. Though PO-HPD patients had better 6- and 12-month survivals, their 2-year survival was worse than stage-IV patients.

Risk factors associated with PO-HPD

Univariate and multivariate analyses were conducted to explore the associations between preoperative risk factors and different timings of recurrence (Table 4). The final results showed that RBC < 3.94 × 10⁹/L (odds ratio [OR] 2.49, 95% CI 1.44–4.33, P = 0.001), CA19–9 ≥ 288.6 U/mL (OR 2.30, 95% CI 1.47–3.59, P < 0.0001), CA125 ≥ 22.3 U/mL (OR 1.78, 95% CI 1.14–2.77, P = 0.011) and tumor size ≥ 3.45 cm (OR 2.32, 95% CI 1.48–3.63, P < 0.0001) were independent preoperative risk factors for PO-HPD patients. The area under the curve (AUC) in ROC curve analysis of logistic regression for the above factors was 0.739 (95% CI 0.690–0.788) (Fig. 2). The sensitivity and specificity were 56.1 and 79.1%, respectively.

Molecular features of patients

By retrospectively collected all the patients’ data, 113 (25 in PO-HPD, 72 in ER, and 16 in LR) patients’ samples were profiled by targeted NGS panel and available for NGS data. Comparison between selected 113 patients with whole population showed no difference in clinicopathological features (Supplementary Table 1). The gene mutation distributions were compared between the PO-HPD and other (ER and LR) patients to assess the molecular features of the former (Fig. 3 and Supplementary Table 2). Mutations of ATR (2/25, 8%), JAKT (2/25, 8%),
Table 1  Baseline demographic, clinicopathologic, treatment characteristics and follow-up data of included patients

| Variable                              | N = 976 | Recurrence (718) | No Recurrence (258) | P     |
|---------------------------------------|---------|-------------------|----------------------|-------|
| Female(%)                             | 266 (37.0%) | 111 (43.0%)       | 0.091                |
| Age (y, mean ± SD)                    | 62.5(±8.85) | 62.7(±9.38)       | 0.638                |
| WBC(*10^9/L, mean ± SD)               | 6.0(±2.08)  | 6.0(±2.15)        | 0.234                |
| Neutrophil(*10^9/L, mean ± SD)        | 6.3(±12.11) | 4.3(±5.41)        | 0.006                |
| Lymphocyte(*10^9/L, mean ± SD)        | 1.5(±0.64)  | 1.5(±0.63)        | 0.804                |
| Monocyte(*10^9/L, mean ± SD)          | 0.4(±0.34)  | 0.5(±0.39)        | 0.862                |
| Hemoglobin(g/L, mean ± SD)            | 128.6(±16.71) | 126.4(±16.44) | 0.086                |
| Albumin(g/L, mean ± SD)               | 38.9(±5.33) | 39.5(±5.01)       | 0.076                |
| LMR                                   | 4.2(±5.65)   | 3.9(±1.88)        | 0.012                |
| PLR                                   | 155.8(±85.15) | 151.8(±85.08) | 0.229                |
| NLR                                   | 5.1(±10.84)  | 3.4(±4.97)        | 0.034                |
| SIRI                                  | 2.3(±4.75)   | 1.7(±3.31)        | 0.026                |
| CA199 (U/mL, median with IQR)         | 166.3 (44.35–554.60) | 112.7 (29.0–288.9) | <0.0001             |
| CA125 (U/mL, median with IQR)         | 16.8 (10.9–29.6) | 14.9 (10.4–23.2) | 0.012                |
| CEA (ng/mL, median with IQR)          | 3.5 (2.1–6.3) | 3.1 (1.9–4.8)   | 0.016                |
| Borderline resectable                 | 178 (24.8%)  | 48 (18.6%)        | 0.043                |
| Tumor size (cm)                       | 3.0 (2.5–4.0) | 3 (2.0–3.5)      | <0.0001              |
| Operation                             | 468 (65.2%)  | 170 (65.9%)       | 0.943                |
| Distal pancreatectomy                 | 216 (30.1%)  | 75 (29.1%)        | 0.321                |
| Total pancreatectomy                  | 34 (4.7%)    | 13 (5.0%)         | 0.243                |
| Vascular resection                    | 113 (15.7%)  | 40 (15.5%)        | <0.0001              |
| R0 resection                          | 636 (88.6%)  | 244 (94.6%)       | 0.006                |
| Tumor differentiation                 | 267 (37.2%)  | 121 (46.9%)       | 0.006                |
| Well-moderate                         | 451 (62.8%)  | 137 (53.1%)       | 0.054                |
| Poor                                  | 1.0 (0.6–2.0) | 1.5 (0.7–2.0)   | 0.064                |
| AJCC T-stage                          | 504 (70.2%)  | 218 (84.5%)       | <0.0001              |
| T1–2                                  | 214 (29.8%)  | 40 (15.5%)        | <0.0001              |
| AJCC N-stage                          | 315 (43.9%)  | 163 (63.2%)       | <0.0001              |
| 0                                     | 301 (41.9%)  | 79 (30.6%)        | <0.0001              |
| 1                                     | 102 (14.2%)  | 16 (6.2%)         | <0.0001              |
| LNM                                   | 403 (56.1%)  | 95 (36.8%)        | <0.0001              |
| Number of LNM                         | 1 (0–2)      | 0 (0–1)           | 0.0001                |
| Positive lymph node ratio             | 0.06 (0–0.17) | 0 (0–0.08)     | <0.0001              |
| Perineural invasion                   | 690 (96.1%)  | 238 (92.2%)       | 0.014                |
| AJCC stage                            | 291 (40.5%)  | 157 (60.9%)       | <0.0001              |
| ≤ 2A                                  | 427 (59.5%)  | 101 (39.1%)       | <0.0001              |
| Complications                         | 606 (84.4%)  | 209 (81.0%)       | 0.085                |
| < 3                                   | 26 (3.6%)    | 16 (6.2%)         | 0.638                |
| POPFF                                 | 98 (13.6%)   | 36 (14.0%)        | 0.0001                |
and CEBPA (2/25, 8%) were only observed in PO-HPD group. The mutation frequencies of other genes were not significantly different between the two groups (PO-HPD vs. ER + LR).

TMB, MATH, and CNI were also calculated to evaluate gene alterations. No significant difference in these characteristics was found between the two groups (Supplementary Fig. 1). The median TMB (mutations/Mb), MATH, and CNI were 1.2886 and 2.5477, 15.295 and 13.43, and 426.13 and 813.42 in ER + LR and PO-HPD groups, respectively. We further defined two subtypes of CNI (CN gain and CN loss) based on CN burden, and the results showed that CN gain was significantly lower in PO-HPD group ($P = 0.043$, Fig. 4).

**Discussion**

The disease progression of PDAC is extremely rapid that many patients cannot undergo surgery because they are in the advanced stage with loss of 98% healthy life expectancy at the time of diagnosis [14]. Multiple studies have proposed the concept of early recurrence to characterize recurrence that occur within few months of pancreatic cancer resection; however, they did not reach an agreement on cut-off values (varying from 6 to 12 months) and ignored the certain group that might have showed relapse before the first time of their follow-up or postoperative adjuvant therapy. The concept, hyperprogrgression HPD was mostly referred to in the field of immunotherapy, however, growth-stimulating effects from surgical trauma-induced immunosuppression were also mentioned in recent studies [5, 15]. The inflammatory response played a critical role in tumor invasion, progression, and metastasis by promoting tumor angiogenesis and decreasing anticancer effects [15]. According to previous studies, systemic response to tissue damages led to surgeries and the subsequent wound healing triggered a cascade alteration in cellular immunity. The high level of circulating damage-associated molecular patterns induced upregulating inflammation. This surgery-induced immunosuppressive status, which might last from several days to 6 months, was related to cancer outcomes since it created a window for cancer cell proliferation and dormant cancer cell revival, resulting in rapid recurrences [5]. In presented study, the total incidence of complications is highest in HPD group, though without statistical difference, which might indicate an increased trend of postoperative inflammation level in HPD patients.

In this study, we proposed the concept of PO-HPD in PDAC to characterize extremely rapid recurrence that occurred within 2 months following curable-intent resection of PDAC. The presented results demonstrated that 73.6% patients suffered recurrence following resection, of which 14.1% showed relapse within 2 months. The prognosis in PO-HPD group was extremely poor with 1- and 2-year survival rates at 36.6 and 5.9%, respectively, and median OS of 9.8 months, which is shorter than that of ER (14.7 months) and LR (30.8 months) groups. Considering the median survival time of unresectable pancreatic cancer that is reported to be 15–17 months in some clinical studies of non-surgical therapy [16, 17] and the median total survival time of pancreatic cancer patients at stage-IV disease from survival data collected from SEER is calculated to be 10.7 months, the unfavorable outcome suggested that PO-HPD patients rarely derived improvement in survival from surgery. In addition, pancreatectomy is one of the most challenging types of surgery with high morbidity and mortality due to its technical difficulty. Serious complications not only prolonged hospital stay, but also decreased patients’ quality of life, leading to delay or intolerance of systemic therapy [18, 19]. Evidence from recent clinical trials have stated a non-negligible position of systemic therapy for PDAC, and in view of the unsatisfactory survival benefit and

### Table 1 (continued)

| Variable                          | N = 976 | Recurrence (718) | No Recurrence (258) | P       |
|-----------------------------------|---------|------------------|----------------------|---------|
| Adjuvant chemotherapy             | 499 (69.5%) | 449 (61.4%)     | 174 (67.4%)          | 0.057   |
| Gemcitabine                       | 71 (9.9%)  | 13 (5.0%)        | 14 (5.5%)            |         |
| S-1 or Capecitabine               | 44 (6.1%)  | 14 (5.5%)        | 14 (5.5%)            |         |
| Combined a                        | 384 (53.5%) | 147 (57.0%)     | 179 (68.9%)          | <0.0001 |
| OS                                | 15.7 (10.0–23.4) | 17.9 (11.3–36.0) | 17.9 (11.3–36.0)    |         |

SD Standard deviation, WBC White blood cell, ABC Red blood cell, CA19–9 Carbohydrate antigen 19–9, IQR Inter-quarter range, CA125 Carbohydrate antigen 125, CEA Carcinoembryonic antigen, LMR Lymphocyte-monocyte ratio, PLR Platelet-lymphocyte ratio, NLR Neutrophil-lymphocyte ratio, SIRI Systemic inflammatory response index, LNM Lymph node metastasis, POPF Postoperative pancreatic fistula, OS Overall survival

T-stage, N-stage and AJCC stage were referred to the 8th edition of American Joint Committee on Cancer (AJCC) TNM staging manual

* Including gemcitabine + capecitabine, gemcitabine + S-1, gemcitabine + nab-paclitaxel, FOLFIRINOX (5-fluorouracil+ leucovorin+irinotecan+ oxaliplatin), gemcitabine + oxaliplatin, capecitabine + oxaliplatin and S-1 + oxaliplatin
### Table 2 Baseline demographic, clinicopathologic, treatment characteristics and follow-up data according to subgroups

| Variable                        | N = 718 | PO-HPD (101) | ER (418) | LR (199) | P    |
|---------------------------------|---------|--------------|----------|----------|------|
| Female(%)                       |         | 29.7%        | 38.8%    | 37.2%    | 0.239|
| Age (y, mean ± SD)              |         | 60.2 (±9.27) | 63.2 (±8.21) | 61.7 (±8.21) | 0.011|
| BMI (kg/m², mean ± SD)          |         | 22.8 (±2.76) | 22.6 (±3.30) | 22.8 (±2.81) | 0.413|
| WBC (10^9/L, mean ± SD)         |         | 6.3 (±2.42)  | 5.9 (±2.07) | 6.2 (±1.88) | 0.063|
| Neutrophil (10^9/L, mean ± SD)  |         | 7.4 (±14.79) | 5.4 (±10.00) | 7.7 (±14.34) | 0.130|
| Lymphocyte (10^9/L, mean ± SD)  |         | 1.6 (±1.03)  | 1.4 (±0.55) | 1.5 (±0.49) | 0.143|
| Monocyte (10^9/L, mean ± SD)    |         | 0.4 (±0.18)  | 0.4 (±0.42) | 0.5 (±0.20) | 0.001|
| RBC (10^12/L, mean ± SD)        |         | 39.6 (±4.24) | 39.1 (±5.74) | 38.2 (±4.85) | 0.085|
| Albumin (g/L, mean ± SD)        |         | 5.1 (±11.80) | 158.3 (±44.76) | 147.5 (±67.84) | 0.549|
| LMR                             |         | 6.7 (±16.25) | 4.5 (±9.12) | 5.5 (±10.72) | 0.831|
| SIIRI                           |         | 2.5 (±5.40)  | 2.0 (±4.47) | 2.6 (±6.49) | 0.118|
| CA199 (U/mL, median with IQR)   |         | 356.0 (96.2–1319.2) | 170.3 (46.6–630.3) | 102.4 (34.0–288.0) | <0.0001|
| CA125(U/mL, median with IQR)    |         | 22.6 (12.4–35.0) | 17.0 (11.4–30.0) | 14.7 (9.4–23.7) | <0.0001|
| CEA (ng/mL, median with IQR)    |         | 4.0 (2.3–6.8) | 3.7 (2.2–6.2) | 3.2 (1.8–6.6) | 0.250|
| Borderline resectable           |         | 32 (31.7)    | 31.7%     | 32 (16.1%) | 0.002|
| Tumor size (cm, median with IQR)|         | 3.5 (3.0–4.0) | 3.0 (2.5–4.0) | 3.0 (2.5–4.0) | <0.0001|
| Operation                       |         |              |          |          | 0.357|
| Pancreaticoduodenectomy         |         | 65 (64.4%)   | 270 (64.6%) | 133 (66.8%) |      |
| Distal pancreatetomy            |         | 30 (29.7%)   | 124 (29.7%) | 62 (31.2%) |      |
| Total pancreatectomy            |         | 6 (5.9%)     | 24 (5.7%)  | 4 (2.0%)  |      |
| Perioperative transfusion       |         | 74 (73.2%)   | 311 (74.4%) | 160 (80.4%) | 0.212|
| Operation time (min, median with IQR) |     | 300 (240–360) | 300 (223.8–345) | 270 (210–330) | 0.055|
| Bleeding amount (ml, median with IQR) | | 300 (200–600) | 300 (200–500) | 400 (200–500) | 0.581|
| Vascular resection              |         | 21 (20.8%)   | 69 (16.5%) | 23 (11.6%) | <0.0001|
| R0 resection                    |         | 88 (87.1%)   | 469 (87.5%) | 79 (97.5%) | 0.027|
| Tumor differentiation           |         |              |          |          | <0.0001|
| Well-moderate                   |         | 23 (22.8%)   | 137 (32.8%) | 107 (53.8%) |      |
| Poor                            |         | 78 (77.2%)   | 281 (67.2%) | 92 (46.2%) |      |
| Margin                          |         | 1.4 (0.6–2.0) | 1.0 (0.5–2.0) | 1.0 (0.6–2.5) | 0.687|
| AJCC T-stage                    |         |              |          |          | 0.006|
| T1–2                            |         | 66 (65.2%)   | 281 (67.2%) | 157 (78.9%) |      |
| T3–4                            |         | 35 (34.7%)   | 137 (32.8%) | 42 (21.1%) |      |
| AJCC N-stage                    |         |              |          |          | 0.006|
| 0                               |         | 34 (33.7%)   | 184 (44.0%) | 97 (48.7%) |      |
| 1                               |         | 50 (49.5%)   | 164 (39.2%) | 87 (43.7%) |      |
| 2                               |         | 17 (16.8%)   | 70 (16.7%) | 15 (7.5%) |      |
| LNM                             |         | 67 (66.3%)   | 234 (56.0%) | 102 (51.3%) | 0.045|
| Harvested lymph nodes           |         | 13 (6–21)    | 13 (7–19)  | 10 (5.5–15.5) | 0.421|
| Number of LNM                   |         | 1 (0–3)      | 1 (0–2)    | 0 (0–2)    | 0.019|
| Positive lymph node ratio       |         | 0.09 (0–0.2) | 0.06 (0–0.19) | 0.04 (0–0.14) | 0.019|
| Perineural invasion             |         | 91 (90.1%)   | 398 (95.2%) | 192 (96.53%) | 0.199|
| AJCC stage                      |         |              |          |          | 0.010|
| ≤ 2A                            |         | 31 (30.7%)   | 254 (60.8%) | 96 (48.2%) |      |
| >2A                             |         | 70 (69.3%)   | 164 (39.2%) | 103 (51.8%) |      |
| Complications                   |         |              |          |          | 0.267|
| < 3                             |         | 89 (88.1%)   | 351 (84.0%) | 166 (83.4%) |      |
severe surgical trauma-induced immunosuppression status, the role of pancreatic surgery for PO-HPD patients should be prudently assessed.

We identified four independent preoperative risk factors for PO-HPD group, consisting of large tumor size, elevated CA19–9 and CA125, and anemia. The AUC of final logistic regression was 0.739. Tumor size was confirmed to be a significant predictive factor of ER, and 3.0 cm was recommended as an optimal cut-off in some studies [9, 17], with the definition of ER varying from 6 to 12 months postoperatively. ROC curve and associated AUC analysis in our study revealed a similar optimal tumor size threshold of 3.45 cm for prediction of PO-HPD.

Despite approximately 5 to 10% population with no or scarce secretion [20], CA19–9 was considered the most studied and well-known biomarker for PDAC [21]. Several studies have demonstrated that increased preoperative CA19–9 was associated with short post-pancreatectomy DFS and decreased life expectancy. Previous studies have explored the threshold of CA19–9 for early recurrence prediction but did not attain consensus. Viencent P. et al. [9]'s study found a preoperative CA19–9 of >210 U/mL as optimal cut-off to predict recurrence within 12 months while Kim et al. and Sugiura et al. reported favorable predictive capability of preoperative CA19–9 >100 U/mL for recurrence within 6 months. Another multi-center study which analyzed resectable PDAC patients identified preoperative CA19–9 >300 U/ml as predictive risk factor for recurrence within 6 months. Similarly, elevated CA19–9 was regarded as a risk factor of PO-HPD in this study and the cut-off was set at 288.6 U/mL according to ROC curve analysis, with an AUC of 0.628.

CA125 was employed as a biomarker for numerous cancers, especially for ovarian cancer, and its serum level would not be influenced by serum bilirubin levels [22, 23]. Elevated CA125 was observed in approximately 45% patients with pancreatic cancer [24]. Studies by Xianjun Y [20] found that CA125 was a potential biomarker in Lewis-negative patient with pancreatic cancer, and studies by Chan A et al. [25] found integrating CA125, CA19–9, and LAMC2 in one panel could improve the detection ability of CA19–9, implying CA125 could serve as a supplement for CA19–9 in pancreatic cancer monitoring. However, few studies found correlation between preoperative CA125 and recurrence. The results of this study verified

---

**Table 2 (continued)**

| Variable                  | N = 718 | PO-HPD (101) | ER (418) | LR (199) | P     |
|---------------------------|---------|--------------|----------|----------|-------|
| ≥ 3 POPF                  |         |              |          |          | 0.766 |
| Biochemical leak          |         |              |          |          | 0.160 |
| Grade B/C POPF            |         |              |          |          |       |
| Adjuvant chemotherapy     |         |              |          |          |       |
| Gemcitabine               |         |              |          |          |       |
| S-1 or Capecitabine       |         |              |          |          |       |
| Combined                  |         |              |          |          |       |
| Recurrence site           |         |              |          |          |       |
| Local                     |         |              |          |          | <0.0001 |
| Systemic                  |         |              |          |          |       |
| Multiple                  |         |              |          |          |       |
| Not know                  |         |              |          |          |       |
| mDFS                      |         |              |          |          |       |
| mOS                       |         |              |          |          |       |
| Median total survival     |         |              |          |          |       |

SD Standard deviation, BMI Body mass index, WBC White blood cell, RBC Red blood cell, CA19–9 Carbohydrate antigen 19–9, IQR Inter-quarter range, CA125 Carbohydrate antigen 125, CEA Carcinoembryonic antigen, LMR Lymphocyte-monocyte ratio, PLR Platelet-lymphocyte ratio, NLR Neutrophil-lymphocyte ratio, SIRI Systemic inflammatory response index, LNM Lymph node metastasis, DFS Disease-free survival, OS Overall survival

T-stage, N-stage and AJCC stage were referred to the 8th edition of American Joint Committee on Cancer (AJCC) TNM staging manual

Complication classification was referred to the Clavien-Dindo’s classification. POPF Postoperative pancreatic fistula, mDFS Median disease-free survival, mOS Median overall survival

* Including gemcitabine + capecitabine, gemcitabine + S-1, gemcitabine + nab-paclitaxel, FOLFIRINOX (5-fluorouracil + leucovorin + irinotecan + oxaliplatin), gemcitabine + oxaliplatin, capcitabine + oxaliplatin and S-1 + oxaliplatin
preoperative CA125 $\geq 22.3$ U/mL as a risk factor of PO-HPD.

Preoperative anemia (RBC $< 3.94 \times 10^9$/L), seldom mentioned in other studies, was an independent risk factor of PO-HPD. The explanation might be that preoperative anemia patients were more probable to undergo perioperative blood transfusion. In this study, the rates of blood transfusion for patients with RBC $< 3.94 \times 10^9$/L was 79.9% (258/323), and 71.8% (469/653) for patients with normal RBC count. Although few randomized trials explored the correlation between blood transfusion and cancer relapse, it was implied in earlier retrospective studies that perioperative blood transfusion, especially allogeneic blood transfusion, was associated with poor postoperative prognosis in several kinds of solid cancers including pancreatic, liver, colorectal and prostate, and head and neck cancers [26–30]. Evidence derived from a Cochrane Group meta-analysis yielded an odds ratio of 1.42 for the effect of perioperative blood transfusion on cancer recurrence; however, the author did not establish a clear causal relationship considering the heterogeneity [31].

Besides preoperative factors, we explored the molecular features of PO-HPD patients. Previous studies reported KRAS, TP53, SMAD4, and CDKN2A as the four major driver genes associated with poor prognosis of pancreatic cancer [32]. In the present study, we observed higher mutation frequencies of these four genes in PO-HPD without significant difference, which might be attributed to the small sample size. It was unexpected that mutations of CEBPA, ATR, and JAK1 were only identified in PO-HPD patients. The regulation of CEBPA accelerated cancer progression by disrupting circadian rhythm-signaling pathway [33]. Jiren Zhang et al. [34] proposed a risk score system for pancreatic adenocarcinoma based on CEBPA and other 11 methylation genes.

### Table 3 Survival data of PO-HPD patients and patients with stage IV pancreatic cancer

|                      | PO-HPD (n = 101) | Stage IV (n = 1733) |
|----------------------|------------------|---------------------|
| Median total survival (m, IQR) | 12.5 (10.7–14.4) | 10.7 (4.0–12.0)    |
| 6-month survival     | 76.8%            | 53.4%               |
| 12-month survival    | 36.6%            | 24.3%               |
| 2-year survival      | 5.9%             | 7.1%                |

PO-HPD Postoperative hyper-progression disease, IQR Inter-quarter range
Total survival was counted from the date diagnosed as pancreatic cancer to the date of death or last follow-up


(HIST1H4E, STAMBPL1, PLD3, CEP55, SSBP4, GRIA1, SWAP70, ADCYAP1R1, YPEL3, HOXC4, and IGFBP1), suggesting that CEBPA might be critical for the survival of PDAC. ATR was identified to be involved in homologous recombination repair, and its mutation might lead to homologous recombination deficiency (HRD) [35]. JAK1 was known to drive cancers with microsatellite instability (MSI) and was often seen in mismatch repair deficient (MMRD) PDAC [36]. The certain mutation distribution pattern of PO-HPD offered alternative therapeutic options for patients that might rarely benefit from surgery, considering that the evidence from preclinical experiments and phase-II clinical trials suggested sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitor of pancreatic cancer patients with HRD [37, 38], and guidelines recommended pancreatic cancer patients with MSI as candidates for immune-checkpoint inhibition [39].

Table 4  Univariate and multivariate analysis for associations between preoperative risk factors and PO-HPD of pancreatic ductal adenocarcinoma after resection

| Preoperative variables | mOS (month)(95%CI) | N | Univariate | Multivariate |
|------------------------|--------------------|---|------------|-------------|
|                        | Odds ratio(95%CI)  | P | Odds ratio(95%CI) | P |
| RBC(*10^12/L) ≥ 3.94 vs. < 3.94 | 9.77 (7.51–12.03)/9.33 (6.03–12.64) | 653/323 | 2.36 (1.41–3.97) | 0.001 |
| Albumin (g/U) ≥ 36 vs. < 36 | 10.70 (8.93–12.47)/7.13 (5.53–8.73) | 745/229 | 1.87 (1.06–3.30) | 0.031 |
| CA19-9(U/mL) ≥ 288.6 vs. < 288.6 | 8.57 (6.57–10.57)/11.57 (10.03–13.10) | 322/636 | 2.94 (1.92–4.50) | < 0.0001 |
| CA125(U/mL) ≥ 22.3 vs. < 22.3 | 9.33 (7.31–11.36)/11.00 (7.99–14.04) | 317/634 | 2.26 (1.48–3.44) | < 0.0001 |
| Tumor size (cm) ≥ 3.45 vs. < 3.45 | 9.40 (7.52–11.28)/10.70 (7.36–14.04) | 398/578 | 2.91 (1.89–4.47) | < 0.0001 |
| Borderline resectable vs. Resectable | 9.40 (7.30–12.30)/9.80 (7.37–11.43) | 226/750 | 1.61 (1.03–2.52) | 0.038 |

PO-HPD Postoperative hyper-progression disease, OS Overall survival, CI Confident interval, RBC Red blood cell, CA Carbohydrate antigen

![Fig. 2](Generated by SPSS, IBM SPSS Statistics 22.0)
Zou et al. BMC Cancer          (2022) 22:649

CL Wen et al.’s study [40] proved high CNI as an independent predictive biomarker for early recurrence in PDAC patients. Our results showed higher CNI in PO-HPD patients than ER + LR group, but was not statistically significant. PO-HPD patients showed lower level of CN gain, which was not mentioned in previous studies and need further exploration.

Both in PO-HPD and ER groups, more than half of the patients showed systemic recurrence, supporting the hypothesis that occult micro metastases existed before surgery. It was suggested that the timing of recurrence was important for OS, and systemic therapy was of potential importance for patients at high risk of rapid recurrence [3, 9, 41, 42]. Recent studies have emphasized

---

**Fig. 3** Differences in molecular features between postoperative hyperprogression disease and ER + LR groups. ER: early recurrence; LR: late recurrence. (Generated by FreeBayes, version 1.2.0 and ANNOVAR version 20210710)

**Fig. 4** Dot-box plot of copy number burden in postoperative hyperprogression disease and ER + LR groups. ER: early recurrence; LR: late recurrence. (Generated by R, https://www.r-project.org/, version 3.6.2)
the role of neoadjuvant therapy in borderline/locally advanced PDAC [43–45] and confirmed that neoadjuvant therapy allows initial treatment of occult metastases, downstage large tumors, and improves rates of negative margin, thereby prolonging life expectancy in patients with advanced disease [42]. The results from a meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer emphasized that neoadjuvant treatment appeared to improve OS, which is in accordance with the current result from ESPAC-5F trial (Four arm, international randomised phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer) that neoadjuvant therapy group showed a significant survival advantage at 1 year (77% vs. 42%) [46].

This study has several limitations. First, CA19–9 could be affected by serum bilirubin level and 29% patients in our study had elevated bilirubin, which might detriment the accuracy of CA19–9. Second, the retrospective nature of the study may have induced bias. Third, we excluded few patients with complete clinical data, and the sample size for genomic investigation was small, which might limit the generalizability of our conclusion.

Conclusions

To summarize, we proposed the concept of PO-HPD in PDAC to characterize extremely rapid recurrence that occurred within 2 months of curable-intent resection of PDAC. The prognosis of PO-HPD patients was extremely poor and verged on that of patients receiving non-surgical therapy. RBC < 3.94 × 10^12/L, CA19–9 ≥ 288.6 U/mL, CA125 ≥ 22.3 U/mL, and tumor size ≥ 3.45 cm were identified as independent preoperative risk factors for PO-HPD. Mutations of CEBPA, ATR, and JAK1 were only identified in PO-HPD patients with lower level of CN gain than in other patients. Since PO-HPD patients rarely derived improvement in survival from surgery, clinical strategies to identify patients with high risk of PO-HPD should be more prudent.

Abbreviations

PDAC: Pancreatic ductal adenocarcinoma; PO-HPD: Postoperative hyper-progression disease; ER: Early recurrence; LR: Late recurrence; AJCC: American Joint Committee on Cancer; SEER: Surveillance, Epidemiology, and End Results; NCCN: National Comprehensive Cancer Network; SRI: Systemic inflammatory response index; NLR: Neutrophil-lymphocyte ratio; CA: Carbohydrate antigen; OS: Overall survival; DFS: Disease survival; NGS: Next-generation sequencing; SNV: Single-nucleotide variants; TMB: Tumoral mutational burden; CNV: Copy number variation; MATH: Mutant allele tumor heterogeneity; VAF: Variant allele frequencies; MAD: Median absolute deviation; SD: Standard deviation; IQR: Inter-quartile range; ROC: Receiver operating characteristic; HRD: Homologous recombination deficiency; MSI: Microsatellite instability; MMRD: Mismatch repair deficient.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-09719-6.

Acknowledgements

The authors appreciate all the team members for their help.

Authors’ contributions

Study concepts: SY ZOU, XJ WANG. Study design SY ZOU, XJ WANG, XX LU, XX DENG, BY SHEN. Data acquisition SY ZOU, XJ WANG, HD CHEN, JW LIN, CL WEN, Q ZHAN. Quality control of data and algorithms SY ZOU, XJ WANG, HD CHEN. Data analysis and interpretation SY ZOU, XJ WANG. Statistical analysis SY ZOU, XJ WANG. Manuscript preparation SY ZOU, XJ WANG, HD CHEN, XX LU, XX DENG, BY SHEN. Manuscript editing SY ZOU, XJ WANG, HD CHEN, BY SHEN. Manuscript review XX LU, XX DENG, BY SHEN. The author(s) read and approved the final manuscript.

Funding

The research described in this paper was financially supported by the Medical Engineering Cross Foundation of Shanghai Jiao Tong University (Grant No. ZH2018ZDA01), National Nature Science Foundation of China (Grant No. 81871906), and Translational Medicine Program of Major National Science and Technology Infrastructure (TMSK-2021-507).

Availability of data and materials

The raw/processed data related to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.

Declarations

Ethical approval and consent to participate

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 [5]. The ethics committee of Shanghai Jiao Tong University School of Medicine affiliated with Ruijin Hospital waived the need for informed consent because the study was observational and retrospective. The ethics committee of Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital approved this retrospective study, including patients from the Pancreatic Disease Center.

Consent to publication

All coauthors consent to publication.

Competing interests

The authors have no conflicts of interest to declare.

Author details

1Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No.197, Rui Jin Er Road, Shanghai 200025, China. 2Research Institute of Pancreatic Disease, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
References

1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.

2. Siegel RLMK, Fuchs HE. Jemal a Cancer statistics, 2021. CA: Cancer J Clin. 2021;71(1):7–33.

3. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.

4. Champiat S, Ferrara R, Massard C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018;15(11):748–62.

5. Tang F, Tie Y, Tu C, Wei X. Surgical trauma-induced immunosuppression in cancer: recent advances and the potential therapies. Clin Transl Med. 2020;10(1):199–223.

6. Tempore MA, Malafa MP, Chiorean EG, et al. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Cancer Netw. 2019;17(3):202–10.

7. Zou et al. BMC Cancer (2022) 22:649

8. Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Cancer Netw. 2019;17(3):202–10.

9. Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of cancer recurrence. J Clin Med. 2021;10(2). doi:10.3390/jcm10020270.

10. Luo G, Liu C, Guo M, et al. Potential biomarkers in Lewis negative tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2011;10(1):1327–34.

11. Chen YT, Deng Q, Che X, et al. Impact of body mass index on complications following pancreatectomy: ten-year experience at National Cancer Center in China. World J Gastroenterol. 2015;21(23):7218–24.

12. Luo G, Liu C, Guo M, et al. Potencial biomarkers in Lewis negative patients with pancreatic Cancer. Ann Surg. 2017;265(4):800–5.

13. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983;29(3):549–52.

14. Fielder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13:129.

15. Luo G, Xiao Z, Long J, et al. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg. 2013;17(12):2092–8.

16. Haglund C. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer. 1986;54(6):897–901.

17. Chan A, Prassas I, Dimitromanolakis A, et al. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res. 2014;20(22):5787–95.

18. Busch OR, Hop WC, Marquet RL, Jeekel J. Blood transfusions and local tumor recurrence in colorectal cancer. Evidence of a noncausal relationship. Ann Surg. 1994;220(6):791–7.

19. Heal JM, Chuang C, Blumberg N. Perioperative blood transfusions and prostate cancer recurrence and survival. Ann J Surg. 1988;156(5):374–80.

20. Kneuertz PJ, Patel SH, Chu CK, et al. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma. Ann Surg Oncol. 2011;18(5):1327–34.

21. Chau JK, Harris JR, Seikaly HR. Transfusion as a predictor of recurrence and survival in head and neck cancer surgery patients. J Otolarngol Head Neck Surg. 2010;39(5):516–22.

22. Wang CC, Iyer SG, Low JK, et al. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2009;16(7):1832–42.

23. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006(1):CD005033.

24. Qian ZR, Robinson DA, Nowak JA, et al. Association of alterations in Main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 2018;4(3):e173420.

25. Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic pancreatic Cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(24):2545–66.

26. Chau J, Kwon O, Lee G, et al. Defining the role of hypoxia-inducible factor-1α (HIF-1α) expression in the resistance to antiangiogenic therapy in pancreatic cancer. Biomed Res Int. 2013;2013:798054.

27. Wang CC, Iyer SG, Low JK, et al. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2009;16(7):1832–42.

28. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006(1):CD005033.

29. Qian ZR, Robinson DA, Nowak JA, et al. Association of alterations in Main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 2018;4(3):e173420.

30. Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic pancreatic Cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(24):2545–66.

31. Wen C, Deng X, Ren D, et al. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Cancer Med. 2020;9(20):7626–36.

32. Groot VP, Bezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267(5):936–45.

33. Kim N, Han IW, Ryu Y, et al. Predictive nomogram for early recurrence after pancreatectomy for pancreatic ductal adenocarcinoma. World J Surg. 2020;44(8):1734–42.

34. Truty MJ, Kendrick ML, Nagorney DM, et al. Factors predicting response, toxicity, and survival following neoadjuvant chemotherapy for borderline/locally advanced pancreatic Cancer. Ann Surg. 2014;260(2):215–22.
45. Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized Chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–9.

46. Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–58.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.